Treprostinil—one molecule over the course of disease

For the treatment of PAH (WHO Group 1), United Therapeutics offers a prostacyclin analog in a range of treprostinil formulations (oral, inhaled, and SC/IV)1-3

Start early with Orenitram (oral treprostinil) for functional class II/III patients to improve exercise capacity. Add Tyvaso (treprostinil inhalation) to background (ERA or PDE-5i) therapy in functional class III patients when inhaled delivery is most appropriate to improve exercise ability
Consider returning to Orenitram for functional class I/II hemodynamically stable Remodulin patients. Choose Remodulin (treprostinil injection or infusion) for functional class II-IV patients to diminish symptoms associated with exercise.
Consider returning to Orenitram for functional class I/II hemodynamically stable Remodulin patients. Start early with Orenitram (oral treprostinil) for functional class II/III patients to improve exercise capacity.
Add Tyvaso (treprostinil inhalation) to background (ERA or PDE-5i) therapy in functional class III patients when inhaled delivery is most appropriate to improve exercise ability
Choose Remodulin (treprostinil injection or infusion) for functional class II-IV patients to diminish symptoms associated with exercise.

FC=functional class; IV=intravenous; PAH=pulmonary arterial hypertension; SC=subcutaneous; WHO=World Health Organization.

Stay with treprostinil across stages of PAH

  • VISIT THE
    ORENITRAM
    WEBSITE

  • VISIT THE
    TYVASO
    WEBSITE

  • VISIT THE
    REMODULIN
    WEBSITE

TREPROSTINIL

4 routes of administration for therapeutic customization1-3

EFFECTIVE
  • Clinical studies demonstrate efficacy across formulations1-3
FLEXIBLE
  • 1 molecule with 4 routes of administration1-3
  • Adaptive dosing to clinical effect and tolerability1-3
ESTABLISHED
  • Over 15 years of clinical experience3
  • More than 27,000 patients treated4